Pharmacogenomics is changing how healthcare professionals understand the relationship between medicines and the human body. Traditionally, doctors have often relied on a patient’s medical history, symptoms, age, health conditions, and treatment response to select an appropriate medication. Although this approach remains essential, it does not always explain why the same medicine works well for one person but causes side effects or produces limited results in another.
This is where pharmacogenomics becomes important. It examines how a person’s genetic variations can influence the way their body responds to particular medicines. By understanding these differences, healthcare professionals may be able to select more suitable treatments, adjust certain doses, and reduce the risk of specific medication-related problems.
The field combines pharmacology, which is the study of medicines, with genomics, which examines genes and their functions. Its goal is to support more personalised healthcare by using genetic information alongside other clinical factors when making treatment decisions.
Although pharmacogenomics cannot guarantee that a medicine will work or eliminate every possible side effect, it offers valuable information that can help make some treatment decisions more precise. As research develops, this approach is becoming an increasingly important part of personalised medicine.
Table of Contents
What Is Pharmacogenomics?
Pharmacogenomics is the study of how a person’s genetic makeup influences their response to medicines. It focuses on identifying genetic variations that may affect how drugs are absorbed, transported, broken down, or used by the body.
People can respond differently to the same medication for several reasons. Some differences are related to age, body composition, liver or kidney function, existing medical conditions, and other medicines being taken. Genetic variation is another important factor.
For example, certain genes provide instructions for producing enzymes responsible for breaking down medications. If a person has a genetic variation that changes how one of these enzymes functions, their body may process a particular medicine more slowly or more quickly than expected.
This difference can influence the amount of medicine present in the bloodstream and may affect its effectiveness or the likelihood of adverse reactions.
Pharmacogenomics helps healthcare professionals understand these gene-drug relationships and determine whether genetic information is relevant to a particular treatment.
How Does Pharmacogenomics Work?
Pharmacogenomics works by examining selected genetic variations that have an established relationship with particular medicines. The information is generally obtained through a pharmacogenomic test, which analyses a biological sample to identify relevant genetic markers.
A typical process involves several stages.
1. Collecting a Genetic Sample
A healthcare professional may recommend a genetic test when a particular medicine has a clinically meaningful relationship with specific genetic variations.
Depending on the testing method, a sample may be collected using a cheek swab, saliva sample, or blood sample. The sample is sent to a suitable laboratory for analysis.
2. Identifying Relevant Genetic Variations
The laboratory examines selected genes or genetic markers associated with medication response. These may include genes involved in drug metabolism, drug transport, or the immune system’s response to certain medicines.
Not every genetic variation has clinical importance. Testing is most useful when scientific evidence establishes that a particular gene-drug relationship can influence treatment decisions.
3. Interpreting the Results
Once testing is complete, the results are interpreted to determine whether the identified genetic variations may affect how the patient responds to a particular medication.
Some results may indicate that a person is likely to process a drug more slowly or quickly than expected. Others may identify an increased risk of a specific adverse reaction.
The interpretation must be based on reliable clinical guidelines and the medication involved. A genetic result should not be treated as a general prediction of how someone will respond to every medicine.
4. Supporting Treatment Decisions
Healthcare professionals can use relevant pharmacogenomic information alongside the patient’s medical history, current medicines, clinical condition, and treatment goals.
Depending on the evidence, the information may support a standard dose, a different dose, an alternative medicine, or additional monitoring.
The objective is to make treatment decisions more informed rather than replacing professional medical judgement.
What Are the Main Benefits of Pharmacogenomics?
Pharmacogenomics has the potential to improve medication management by helping healthcare professionals understand differences in drug response. Its benefits depend on the specific medicine, genetic marker, and quality of available clinical evidence.
1. Supporting More Personalised Treatment
Traditional treatment approaches often begin with standard prescribing recommendations. However, a standard treatment may not be equally suitable for every patient.
Pharmacogenomic information can help identify patients who may respond differently to certain medicines. This allows healthcare professionals to consider individual genetic differences when selecting treatment.
Personalised treatment does not mean that every patient needs a separate medicine. Instead, it means using relevant patient information to make more appropriate decisions.
2. Helping Identify the Appropriate Medication
Finding an effective medicine can sometimes involve trying different treatment options. This may be particularly challenging when a patient has a condition that requires long-term medication or has not responded well to previous treatments.
When strong evidence supports a gene-drug relationship, pharmacogenomic information may help clinicians identify medicines that are more suitable for a particular patient.
However, genetic testing cannot identify the best medicine for every condition. Diagnosis, treatment guidelines, patient preferences, and other clinical factors remain important.
3. Reducing the Risk of Certain Medication Side Effects
Some genetic variations can increase the likelihood of specific adverse drug reactions. Identifying these variations before treatment may help healthcare professionals avoid particular medicines or consider alternative treatment strategies.
For example, certain genetic markers are associated with serious reactions to specific medications. Testing for HLA-B*57:01 before prescribing abacavir is an established example of pharmacogenomic testing used to reduce the risk of a serious hypersensitivity reaction.
Pharmacogenomics may also help explain why some patients experience unwanted effects from medicines that are generally well tolerated by others.
Patients who want to understand medication-related reactions can also explore Viagra side effects and how to minimise them naturally. However, general side-effect advice and pharmacogenomic testing serve different purposes, and genetic testing is not routinely required for every medication.
4. Supporting More Appropriate Medication Dosing
The amount of medicine a patient needs can vary depending on several factors, including genetic differences in drug metabolism.
Some people may break down a particular medicine more slowly, potentially increasing drug exposure. Others may process it more rapidly, which can affect the amount of active medicine available in the body.
When supported by clinical evidence, pharmacogenomic information can help healthcare professionals determine whether a dose adjustment or alternative medicine should be considered.
Any dosage decision must follow the relevant prescribing guidance and account for the patient’s overall health.
5. Improving Medication Safety
Medication safety is a major concern in modern healthcare. Patients may experience adverse reactions because of incorrect doses, interactions, allergies, underlying health conditions, or differences in how their bodies process medicines.
Pharmacogenomics provides another source of information that can help identify certain genetic risks before or during treatment.
It may also help healthcare professionals recognise situations where additional monitoring or a different medication is appropriate.
Nevertheless, genetic information does not replace standard safety checks, medication reviews, or clinical monitoring.
6. Supporting More Efficient Healthcare
An unsuitable medication can sometimes lead to additional consultations, treatment changes, monitoring, and healthcare expenses.
When pharmacogenomic information helps identify an appropriate treatment strategy, it may reduce some avoidable medication-related problems.
Potential financial benefits depend on the medicine, testing costs, healthcare system, and whether the test produces an actionable result. Genetic testing should therefore be considered when its expected clinical value justifies its cost.
Examples of Important Gene-Drug Relationships
Pharmacogenomics becomes easier to understand when looking at examples of how specific genes can influence medication response.
CYP2D6 and Certain Medicines
The CYP2D6 gene provides instructions for producing an enzyme involved in processing several medicines. Genetic differences can cause people to metabolise certain drugs at different rates.
Depending on the medication, a person may be classified as a poor, intermediate, normal, or ultrarapid metaboliser.
These differences can influence the effectiveness or safety of certain treatments. However, the clinical significance varies between medicines, so the result must be interpreted in the context of the specific drug.
CYP2C19 and Clopidogrel
Clopidogrel is an antiplatelet medicine used to reduce the risk of blood clots in certain patients. It requires activation in the body, and the CYP2C19 enzyme plays an important role in this process.
Some genetic variations reduce CYP2C19 activity. In affected patients, clopidogrel may not be activated as effectively, potentially reducing its antiplatelet effect.
For certain clinical situations, pharmacogenomic guidance may help healthcare professionals consider alternative treatment options.
HLA-B*57:01 and Abacavir
Abacavir is an antiretroviral medicine used in the treatment of HIV. People who carry the HLA-B*57:01 genetic variant have a substantially increased risk of developing a serious hypersensitivity reaction to this medicine.
Testing for this variant before starting abacavir is an established safety measure. Patients who test positive should not receive the medication.
These examples demonstrate why pharmacogenomic information can be clinically useful. They also show that recommendations are specific to particular gene-drug relationships rather than applying to all medicines.
When Should Someone Consider Pharmacogenomic Testing?
Pharmacogenomic testing may be considered when a medication has an established genetic association and the result could influence treatment decisions.
A healthcare professional may discuss testing in situations such as:
- A medicine has a recognised gene-drug interaction with established prescribing recommendations.
- A patient has experienced an unexpected response to a particular medication.
- A treatment requires specific genetic testing before it can be prescribed safely.
- A patient is starting a medicine for which genetic information may influence the dose or selection of treatment.
- Previous treatment attempts have been unsuccessful and an evidence-supported genetic test may provide useful information.
Testing may also be considered as part of a broader personalised medicine programme in certain healthcare settings.
However, pharmacogenomic testing is not necessary for every patient or every prescription. Its usefulness depends on whether a clinically meaningful gene-drug relationship exists and whether the result can guide a practical treatment decision.
What Are the Limitations of Pharmacogenomics?
Although pharmacogenomics offers important opportunities, it has limitations that patients and healthcare professionals should understand.
Genetic Information Does Not Explain Every Drug Response
A person’s genes are only one part of medication response. Other factors, such as age, weight, liver and kidney function, existing health conditions, diet, smoking, alcohol use, and interactions with other medicines, can also influence treatment outcomes.
A genetic test cannot account for every factor that affects how a medicine works.
Not Every Gene-Drug Relationship Is Clinically Actionable
Researchers have identified many possible relationships between genes and medication response. However, not all of these relationships have sufficient evidence to support a change in treatment.
Some genetic variations may affect drug concentrations without clearly demonstrating that changing the medication improves clinical outcomes.
Healthcare professionals should rely on established evidence and prescribing recommendations rather than assuming that every result requires a treatment change.
Testing Can Involve Additional Costs
The cost of genetic testing varies according to the number of genes examined, laboratory methods, healthcare provider, and location.
Some tests may be covered by insurance or healthcare programmes, while others may require patients to pay themselves.
Patients should understand the cost, purpose, and potential clinical value of a test before proceeding.
Genetic Privacy Must Be Protected
Genetic information is personal and may reveal details about an individual’s biological characteristics. Healthcare providers and testing laboratories should follow applicable privacy and data protection requirements.
Patients should understand how their samples and results will be stored, who can access the information, and whether it may be used for additional purposes.
Results Require Professional Interpretation
A genetic report can contain technical information that is difficult to understand without appropriate training.
The results should be reviewed by a qualified healthcare professional who can explain their relevance to the patient’s medicines and overall health.
Patients should not stop, start, or change medication doses based only on a genetic test report.
Pharmacogenomics and the Future of Personalised Medicine
The future of pharmacogenomics is closely connected to the wider development of personalised medicine. Advances in genetic testing, laboratory technology, and clinical decision-support systems are making it easier to identify and interpret certain gene-drug relationships.
Healthcare organisations are also exploring ways to incorporate genetic information into electronic health records. When relevant results are available during prescribing, clinical systems may help alert healthcare professionals to important medication-related considerations.
Artificial intelligence and data analysis may also support research by helping scientists investigate complex relationships between genetic variations, medicines, and treatment outcomes. However, these technologies still require reliable clinical evidence and appropriate professional oversight.
Another important development is the growth of pharmacogenomic guidelines. Organisations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) publish evidence-based recommendations to help healthcare professionals understand how available genetic results can guide medication decisions.
As research expands, more gene-drug relationships may become clinically useful. However, the future of pharmacogenomics will depend not only on discovering genetic associations but also on demonstrating that using this information improves patient care.
Conclusion: What Pharmacogenomics Means for Your Health
Pharmacogenomics represents an important development in personalised healthcare. By examining how genetic differences influence medication response, it can help healthcare professionals make more informed decisions about certain medicines, doses, and potential safety risks.
Its benefits include supporting individualised treatment, identifying selected gene-related adverse reaction risks, and improving medication selection when strong clinical evidence is available.
However, pharmacogenomics is not a universal solution. Genetic information is only one part of a patient’s overall health profile, and not every genetic finding has a practical effect on treatment.
For patients, the most important step is to discuss the potential value of pharmacogenomic testing with a qualified healthcare professional. When used appropriately, it can provide useful information that supports safer, more personalised, and evidence-based medication decisions.